A bioluminescent inhibition immunoassay for detecting GM-CSF inhibitory activity in serum
Clinical and Experimental Immunology · 06.01.2026 · 220 (1)
DOI: 10.1093/cei/uxag027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 14.05.2026. Verfasst von Peter Bradhurst und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia. Hauptthemen laut MEDLINE: Granulocyte-Macrophage Colony-Stimulating Factor, Autoantibodies, Pulmonary Alveolar Proteinosis, Luminescent Measurements. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: RCPA Foundation.
Abstract (Originalsprache)
Autoantibodies against granulocyte–macrophage colony-stimulating factor (GM-CSF) are the cause of autoimmune pulmonary alveolar proteinosis (aPAP). They are also found in the serum/plasma of previously immunocompetent patients with disseminated Cryptococcus spp. infection (typically spp. gattii) and disseminated Nocardia spp. infection. Detection of this autoantibody is generally performed through an antibody binding assay, followed by a live-cell–based pSTAT5 neutralization to confirm functional significance of detected autoantibodies. The requirement for a live-cell–based assay increases the technical difficulty of diagnosis and means that this testing is generally only offered in specialist research centres. We report a bioluminescent immunoassay (BLIA) platform, which accurately detects inhibition of GM-CSF detection in serum. The BLIA method has previously been described in detail to detect anti-cytokine autoantibodies against IFNγ. The BLIA platform was able to distinguish 24 blinded disease control samples with 100% accuracy when compared with gold standard testing. We sought referrals for patients with aPAP, Cryptococcus spp. Infection, and Nocardia spp. infection to test the performance of this assay. Positive results were seen in 100% of patients with clinically confirmed aPAP and a proportion of patients with disseminated Cryptococcus or Nocardia spp. infection. We conclude that the BLIA is technically simple, rapid, and easily automatable and could be easily employed in a diagnostic laboratory. The performance characteristics of the BLIA result in rapid and accurate screening of patients with these uncommon autoantibody-mediated conditions, allowing for quick diagnosis and referral for specialist management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.
- Institute of Academic Medicine, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.
- Faculty of Health and Medicine, University of Sydney, Camperdown, NSW 2050, Australia.
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.
ORCID-Profile: Peter Bradhurst
Förderung
- RCPA Foundation
Zitieren
APA
Bradhurst, P., Stoyanov, A., Rosen, L. B., Holland, S. M., Guy, T. V., & Urriola, N. (2026). A bioluminescent inhibition immunoassay for detecting GM-CSF inhibitory activity in serum. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag027
Vancouver
Bradhurst P, Stoyanov A, Rosen LB, Holland SM, Guy TV, Urriola N. A bioluminescent inhibition immunoassay for detecting GM-CSF inhibitory activity in serum. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag027
BibTeX
@article{Bradhurst2026,
author = {Bradhurst, Peter and Stoyanov, Alex and Rosen, Lindsey B and Holland, Steven M and Guy, Thomas V and Urriola, Nicolás},
title = {A bioluminescent inhibition immunoassay for detecting GM-CSF inhibitory activity in serum},
journal = {Clinical and Experimental Immunology},
year = {2026},
volume = {220},
number = {1},
doi = {10.1093/cei/uxag027}
}
EUVIMED